

Row No	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
1	18/LO/2140	246772	Post-Market Study to evaluate Real-world outcomes and treatment Practices for the CENTERA? TranScatheter Heart Valve (THV) System	No					01/10/2018	01/02/2019	01/02/2019				C - Closed by sponsor	Sponsor
2	18/EM/0298	251419	A Phase 3b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of TRC101 in Delaying Chronic Kidney Disease Progression in Subjects with Metabolic Acidosis	No		11			25/09/2018	11/02/2019	21/11/2018	14/01/2019	22/02/2019	11/03/2019	F - No patients seen	Neither
3	18/EM/0184	233744	Desmopressin for reversal of Antiplatelet drugs in Stroke due to Haemorrhage (DASH)	No		16			28/11/2018	12/02/2019	04/09/2018	18/02/2019	28/02/2019	27/03/2019	F - No patients seen	Neither
4	16/SS/0137	199347	Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)	No		33			14/11/2017	22/02/2019	11/01/2017	20/03/2019	27/03/2019		E - Staff availability issues	NHS Provider
5	18/EE/0296	250366	A Phase I, Open Label, Randomized, Parallel Group, Multicentre study to Compare the Effect of AZD9977 and Spironolactone on Serum Potassium [sK+] during 28 days in Patients with HFmrEF or HFpEF and eGFR in the range of =40 and =70 mL/min/1.73m2	Yes	02/12/2019	40	252	292	03/09/2018	13/02/2019	18/01/2019	19/02/2019	25/03/2019	04/04/2019	F - No patients seen	Neither
6	16/SW/0232	201854	Rifaximin to Reduce Infection in Decompensated Cirrhosis	No		43			07/08/2018	19/03/2019	31/10/2016	05/06/2019	01/05/2019	07/08/2019	D - Sponsor Delays	Sponsor
7	16/NW/0620	206738	Phase 3, randomized, open-label, active-controlled study evaluating the efficacy and safety of oral vadadustat for the correction of anemia in subjects with non-dialysis-dependent chronic kidney disease (NDD-CKD) (PRO2TECTCORRECTION)	No		1			14/12/2018	01/04/2019	17/11/2016	20/03/2019	02/04/2019	11/04/2019	F - No patients seen	Neither
8	19/EM/0112	259565	Proof-of-mechanism study of QAW039 (fevipirant) in eosinophilic COPD	No		46			25/03/2019	22/04/2019	21/05/2019	03/06/2019	07/06/2019	12/06/2019	F - No patients seen	Neither
9	19/YH/0093	255567	A Randomized Open-Label, Phase 1b Study of the Safety of Pirfenidone Solution for Inhalation (AP01) in Patients with Idiopathic Pulmonary Fibrosis (ATLAS Study)	Yes	21/11/2019	98	129	227	03/09/2018	08/04/2019	04/06/2019	05/07/2019	15/07/2019	06/08/2019	D - Sponsor Delays	Sponsor
10	19/YH/0097	261131	Peanut Oral Immunotherapy Study of Early Intervention for Desensitization	No		7			25/02/2019	13/06/2019	28/05/2019	17/06/2019	20/06/2019	03/07/2019	F - No patients seen	Neither
11	18/EE/0099	239606	An open-label, randomised, phase III Study comparing trifluridine/tipiracil (S 95005) in combination with bevacizumab to capecitabine in combination with bevacizumab in first-line treatment of patients with metastatic colorectal cancer who are not candidate for intensive therapy (SOLSTICE study)	Yes	01/11/2019	38	161	199	19/12/2018	16/04/2019	01/06/2018	13/05/2019	24/05/2019	29/05/2019	F - No patients seen	Neither
12	18/LO/0513	230722	A Phase II Double-blind, Randomised, Parallel Group 2:1 Comparison of the Efficacy and Safety of FP-1201-lyo (Recombinant Human Interferon beta-1a) and Placebo in the Prevention of Multi-Organ Failure on Patients Surviving Open Surgery for a Ruptured Abdominal Aortic Aneurysm	No					02/05/2017	21/06/2019	10/10/2018				D - Sponsor Delays	Sponsor
13	18/WM/0025	233804	Sub-acromial spacer for Tears Affecting Rotator cuff Tendons: a Randomised, Efficient, Adaptive Clinical Trial in Surgery	Yes	01/08/2019	16	175	191	19/09/2018	22/01/2019	13/02/2018	11/02/2019	07/02/2019	15/02/2019	I - Rare diseases	Neither
14	19/SW/0140	265506	A Randomised, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab Compared to Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA) in Patients Receiving Standard of Care Therapy	No		129			25/06/2019	25/06/2019	20/08/2019	22/10/2019	01/11/2019		D - Sponsor Delays	Sponsor
15	18/LO/0430	241907	An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura	Yes	19/08/2019	15	174	189	13/08/2018	11/02/2019	11/06/2018	15/11/2018	26/02/2019	18/07/2019	C - Closed by sponsor	Sponsor

Row No	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
16	19/SC/0151	253737	SMARTHEART validation study - A study to assess the accuracy and validate novel smartphone and wearable ECG devices in cardiovascular patients	No		35			13/11/2018	25/06/2019	17/05/2019	24/07/2019	30/07/2019	30/07/2019	F - No patients seen	Neither
17	19/NI/0037	250757	A phase 1, open-label, single dose, non-randomized study to evaluate pharmacokinetics, pharmacodynamics, and safety of Betrixaban in pediatric patients.	Yes	02/10/2019	171	14	185	13/02/2019	31/03/2019	26/03/2019	16/09/2019	18/09/2019	20/09/2019	D - Sponsor Delays	Sponsor
18	19/YH/0094	256470	A PHASE 4 RANDOMIZED CLINICAL TRIAL OF ANDEXANET ALFA [ANDEXANET ALFA FOR INJECTION] IN ACUTE INTRACRANIAL HEMORRHAGE IN PATIENTS RECEIVING AN ORAL FACTOR XA INHIBITOR	No		20			30/04/2019	04/07/2019	19/06/2019	27/06/2019	24/07/2019	09/08/2019	F - No patients seen	Neither
19	18/WA/0262	245893	A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with Focal Segmental Glomerulosclerosis (FSGS)	No		4			29/03/2019	11/07/2019	26/10/2019	07/07/2019	15/07/2019		E - Staff availability issues	NHS Provider
20	18/SS/0079	226923	Multi-center, blinded, randomized, PaRallEl-group, Phase 3 study with aproClitentan in Subjects with resistant hypertension.	No		22			08/02/2018	15/07/2019	20/08/2019	15/07/2019	06/08/2019	11/09/2019	F - No patients seen	Neither
21	19/NW/0181	260431	A Randomized, Double-blind, Placebo-Controlled, Crossover, Dose Escalation Study of BLU-5937 in Subjects with Unexplained or Refractory Chronic Cough	Yes	03/10/2019	137	31	168	03/04/2019	18/04/2019	14/06/2019	06/08/2019	02/09/2019	10/09/2019	E - Staff availability issues	NHS Provider
22	17/EE/0327	224081	A RANDOMISED CONTROLLED TRIAL OF RED CELL REJUVENATION FOR THE ATTENUATION OF TRANSFUSION ASSOCIATED ORGAN INJURY IN CARDIAC SURGERY: The REDJUVENTATE Trial	No		21			07/02/2017	18/07/2019	20/11/2017	18/01/2018	08/08/2019		D - Sponsor Delays	Sponsor
23	19/WM/0097	246910	A randomised controlled trial to study the effectiveness of sMoking cessation in the sURgical pathway befoRe mAjor lung sugerY. Project MURRAY: Feasibility Study	No					25/04/2019	22/07/2019	11/07/2019				D - Sponsor Delays	Sponsor
24	19/EM/0031	254100	Understanding the Electrophysiological Substrate in Persistent Atrial Fibrillation - II (USURP AF-study II)	Yes	10/09/2019	44	117	161	03/10/2018	02/04/2019	14/02/2019	16/05/2019	16/05/2019	17/05/2019	F - No patients seen	Neither
25	19/SW/0041	260477	A Phase 3, multicenter, randomized, open-label trial to compare the efficacy and safety of pembrolizumab (MK-3475) in combination with lenvatinib (E7080/MK-7902) versus docetaxel in previously treated participants with metastatic non-small cell lung cancer (NSCLC) and progressive disease (PD) after platinum doublet chemotherapy and immunotherapy (anti-PD-1/PD-L1 inhibitor) (LEAP-008)	Yes	18/11/2019	21	140	161	19/12/2018	10/06/2019	02/04/2019	21/06/2019	01/07/2019	05/07/2019	F - No patients seen	Neither
26	19/EM/0060	260387	A Phase 2, Randomized, Double-blind, Placebo-controlled Study of Cemdisiran in Adult Patients with IgA Nephropathy	No		0			22/01/2019	25/07/2019	04/02/2019	21/06/2019	25/07/2019	01/08/2019	F - No patients seen	Neither
27	15/WA/0392	169633	A randomised Phase II/III trial to study radiotherapy dose escalation in patients with oesophageal cancer treated with definitive chemoradiation with an embedded Phase II trial for patients with a poor early response using positron emission tomography (PET)	Yes	26/11/2019	16	139	155	13/04/2018	24/06/2019	15/06/2016	23/05/2019	10/07/2019	17/07/2019	F - No patients seen	Neither
28	17/EM/0440	230556	DANTE: A randomised phase III trial to evaluate the Duration of ANti-PD1 monoclonal antibody Treatment in patients with metastatic mElanoma	Yes	30/09/2019	43	111	154	05/02/2018	29/04/2019	18/01/2018	29/05/2019	11/06/2019	18/06/2019	F - No patients seen	Neither
29	19/YH/0026	256695	A first in human, double-blind, placebo-controlled, multicentre Phase I/II study to evaluate the safety, tolerability and immune modulatory effects of MRx-4DP0004 (a lyophilised formulation of Bifidobacterium breve proprietary strain of 4D Pharma Research) in participants taking long-term control medication for their asthma	Yes	17/10/2019	9	141	150	19/02/2019	20/05/2019	09/04/2019	16/05/2019	29/05/2019	24/07/2019	D - Sponsor Delays	Sponsor

Row No	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
30	19/EE/0185	260536	FIRST-line support for Assistance in Breathing in Children (FIRST-ABC): A master protocol of two randomised trials to evaluate the non-inferiority of high flow nasal cannula (HFNC) versus continuous positive airway pressure (CPAP) for non-invasive respiratory support in paediatric critical care	Yes	02/11/2019	88	61	149	05/06/2019	06/06/2019	26/07/2019	02/09/2019	02/09/2019	24/10/2019	D - Sponsor Delays	Sponsor
31	18/NE/0296	248487	Carvedilol versus variceal Band ligation in primary prevention of variceal bleeding in liver cirrhosis	Yes	20/11/2019	0	149	149	11/09/2018	24/06/2019	19/10/2018	05/03/2019	24/06/2019	27/09/2019	D - Sponsor Delays	Sponsor
32	19/YH/0049	258945	A PHASE I, MULTICENTER, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMIC EFFECTS OF A SINGLE DOSE OF MTPS9579A IN PATIENTS WITH ASTHMA REQUIRING INHALED CORTICOSTEROIDS AND A SECOND CONTROLLER	Yes	05/11/2019	50	97	147	04/02/2018	11/06/2019	30/05/2019	22/07/2019	31/07/2019	01/08/2019	D - Sponsor Delays, F - No patients seen	Sponsor
33	19/LO/0553	257627	GALACTIC-1 - A randomized, double-blind, multicentre, parallel, placebo controlled Phase 2b study in subjects with idiopathic pulmonary fibrosis (IPF) investigating the efficacy and safety of TD139, an inhaled galectin-3 inhibitor administered via a dry powder inhaler over 52 weeks	No		69			13/08/2019	13/08/2019	24/09/2019	21/10/2019	21/10/2019		D - Sponsor Delays	Sponsor
34	19/SW/0093	260867	A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 with Background Treatment in Subjects with Lupus Nephritis	No		45			03/10/2018	19/08/2019	17/06/2019	20/09/2019	03/10/2019	28/10/2019	D - Sponsor Delays, F - No patients seen	Sponsor
35	19/LO/0981	260202	Phase 3 Study of Sacituzumab Govitecan-hziy (IMMU-132) in Relapsed/Refractory HR+/HER2- MBC	No					07/05/2019	20/08/2019	16/08/2019				D - Sponsor Delays	Sponsor
36	19/SC/0021	249552	OPTimal TIMing of Anticoagulation after acute ischaemic Stroke: a randomised controlled trial (OPTIMAS Trial)	No		28			03/04/2019	23/08/2019	04/04/2019	06/09/2019	20/09/2019	08/11/2019	F - No patients seen	Neither
37	16/LO/1318	187932	Nucleos(t)ide withdrawal in HBeAg negative hepatitis B virus infection to promote HBsAg clearance. (NUC-B)	Yes	03/06/2019	69	61	130	22/11/2018	24/01/2019	21/09/2016	28/03/2019	03/04/2019	12/04/2019	D - Sponsor Delays, F - No patients seen	Sponsor
38	18/LO/2033	252294	When to Induce Labour to Limit risk in pregnancy hypertension ? a multicentre, randomised controlled trial	Yes	24/10/2019	20	107	127	12/03/2019	19/06/2019	10/01/2019	05/07/2019	09/07/2019	10/07/2019	E - Staff availability issues	NHS Provider
39	18/SC/0644	242136	Avelumab in the frontline treatment of advanced classical Hodgkin lymphoma - a window study	No		61			22/02/2019	29/08/2019	19/02/2019	18/11/2019	29/10/2019		D - Sponsor Delays, F - No patients seen	Sponsor
40	19/LO/0384	239240	Magnetic Resonance Imaging (MRI) for Aortic Dissection to Visualise Inflammation.	No		118			02/10/2018	10/05/2019	03/05/2019	10/07/2019	05/09/2019	11/09/2019	D - Sponsor Delays	Sponsor
41	18/LO/0555	237992	Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal	No		78			13/06/2019	13/06/2019	19/04/2018	31/07/2019	30/08/2019	15/10/2019	D - Sponsor Delays	Sponsor
42	17/LO/0980	219505	Targeted therapy with or without dose intensified radiotherapy for oligo-progressive disease in oncogene-addicted lung tumours	Yes	15/11/2019	21	100	121	22/02/2018	17/07/2019	10/07/2017	19/08/2019	07/08/2019	23/08/2019	F - No patients seen	Sponsor
43	17/SC/0476	186573	Macular Edema Ranibizumab v. Intravitreal anti-inflammatory Therapy (MERIT) Trial	No		104			14/11/2018	06/09/2019	07/11/2017	04/10/2019	19/12/2019		D - Sponsor Delays	Sponsor
44	18/EM/0254	246009	A RANDOMISED CONTROLLED TRIAL OF A PRE-OPERATIVE HIGH ENERGY DIET FOR THE PREVENTION OF ORGAN INJURY IN CARDIAC SURGERY: THE PRE-OP ENERGY TRIAL	Yes	07/05/2019	69	41	110	13/03/2018	17/01/2019	27/11/2018	27/03/2019	27/03/2019	28/03/2019	D - Sponsor Delays	Sponsor
45	17/SC/0536	216069	A 3-Arm Randomised Phase II Evaluation of Cediranib in Combination with Weekly Paclitaxel or Olaparib Versus Weekly Paclitaxel Chemotherapy as Second-Line Therapy for Advanced/Metastatic Endometrial Carcinoma or for disease relapse within 12 months of adjuvant carboplatin-paclitaxel chemotherapy.	Yes	12/09/2019	35	72	107	31/01/2019	28/05/2019	04/12/2017	24/05/2019	02/07/2019	10/07/2019	F - No patients seen	Neither

Row No	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
46	19/SC/0221	259880	An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy in patients with advanced haematological malignancies.	No		7			14/02/2019	18/09/2019	10/06/2019	24/09/2019	25/09/2019	04/10/2019	F - No patients seen	Neither
47	19/LO/0995	263661	To evaluate the acceptability (including gastro intestinal tolerance and compliance) of a hypoallergenic amino acid infant formula with HMOs for the dietary management of cows? milk allergy in infants less than 12 months of age.	No		5			26/07/2019	20/09/2019	24/06/2019	17/09/2019	25/09/2019	26/09/2019	D - Sponsor Delays	Sponsor
48	19/NE/0235	260081	An International, Phase 3, Multicenter, Randomized, Open Label Trial Comparing Balixafortide In combination with Eribulin versus Eribulin alone in Patients with HER2 negative, Locally Recurrent or Metastatic Breast Cancer.	No					25/02/2019	23/09/2019	13/01/2020				D - Sponsor Delays	Sponsor
49	18/LO/0165	224726	POLEM: Avelumab plus 5-FU based chemotherapy as adjuvant treatment for stage 3 MSI-High or POLE exonuclease domain mutant colon cancer: A phase 3 randomised study.	No		26			22/05/2017	13/06/2019	09/05/2018	02/07/2019	09/07/2019	20/09/2019	D - Sponsor Delays	Sponsor
50	19/LO/1270	261294	CRAFT: Cerclage after full dilatation caesarean section; an investigation into the role of previous in labour caesarean section in future preterm birth risk and potential management strategies	Yes	30/12/2019	14	81	95	15/08/2019	26/09/2019	20/09/2019	19/09/2019	10/10/2019	10/10/2019	D - Sponsor Delays, E - Staff availability issues, F - No patients seen	Both
51	19/LO/0285	256948	A Multicenter Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005)	Yes	13/08/2019	0	92	92	04/10/2018	13/05/2019	30/04/2019	07/05/2019	13/05/2019	16/05/2019	F - No patients seen	Neither
52	19/EM/0057	257429	A Phase 3 Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) with or without Lenvatinib (E7080/MK-7902) as First-line Intervention in Participants with Metastatic Nonsquamous Non-small Cell Lung Cancer (LEAP-006)	No		11			22/10/2018	20/06/2019	08/05/2019	17/06/2019	01/07/2019	19/09/2019	D - Sponsor Delays	Sponsor
53	19/LO/1024	263894	A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Medically Inoperable Stages I or IIA Non Small Cell Lung Cancer (NSCLC) (KEYNOTE-867)	No		56			13/03/2019	02/08/2019	26/07/2019	25/09/2019	27/09/2019	01/11/2019	D - Sponsor Delays	Sponsor
54	16/WS/0114	200445	A PHASE 1, OPEN-LABEL, SINGLE-DOSE, NON-RANDOMIZED STUDY TO EVALUATE PHARMACOKINETICS AND PHARMACODYNAMICS OF EDOXABAN IN PEDIATRIC PATIENTS	Yes	28/10/2019	14	76	90	08/05/2019	30/07/2019	27/09/2016	12/08/2019	13/08/2019	28/08/2019	F - No patients seen	Neither
55	19/EE/0200	265253	A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of Tirzepatide versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients with Type 2 Diabetes (SURPASS-2)	Yes	02/12/2019	28	62	90	22/07/2019	03/09/2019	29/07/2019	30/09/2019	01/10/2019	01/10/2019	D - Sponsor Delays	Sponsor
56	19/EM/0201	261499	A feasibility study of a multi-centre cluster randomised controlled trial (RCT) to investigate whether a new diagnostic pathway is clinically and cost-effective for older adults presenting with chronic breathlessness.	Yes	05/11/2019	27	62	89	22/03/2019	08/08/2019	08/09/2019	19/07/2019	04/09/2019	05/09/2019	F - No patients seen	Neither
57	18/EM/0406	250403	EURO SHOCK Testing the value of novel strategy and its cost efficacy in order to improve the poor outcomes in Cardiogenic Shock	No		27			03/10/2018	04/10/2019	04/03/2019	30/10/2019	31/10/2019		F - No patients seen	Neither
58	19/NW/0021	234848	BIOMarker-guided Treatment decisions In Rheumatoid and Psoriatic Arthritis (BIOTIPRA); A Feasibility Study	No		3			07/03/2019	22/07/2019	06/03/2019	22/07/2019	25/07/2019	15/10/2019	D - Sponsor Delays	Sponsor

Row No	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
59	18/NW/0694	248847	A Phase III, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD).	No		15			03/09/2019	08/10/2019	07/12/2018	21/10/2019	23/10/2019		B - Suspended by sponsor	Sponsor
60	17/EM/0121	221773	A RANDOMIZED, OPEN, MULTINATIONAL, MULTICENTRE, 2-PART STUDY IN SPONTANEOUSLY BREATHING PRETERM NEONATES WITH MILD TO MODERATE RESPIRATORY DISTRESS SYNDROME TO INVESTIGATE THE SAFETY, TOLERABILITY AND EFFICACY OF INHALED NEBULISED PORACTANT ALFA (PORCINE SURFACTANT, CUROSURF?) IN COMPARISON WITH nCPAP ALONE	Yes	18/06/2019	31	53	84	03/09/2018	26/03/2019	22/05/2017	16/04/2019	26/04/2019	17/06/2019	D - Sponsor Delays	Sponsor
61	18/SS/0120	233867	A Randomized, Open-Label Phase II/III Study with Dendritic Cells Loaded With Allogeneic Tumour Cell Lysate (PheraLys) in Subjects with Mesothelioma as Maintenance Treatment (MesoPher) After Chemotherapy	No		1			28/09/2017	08/10/2019	21/12/2018	09/10/2019	09/10/2019	15/10/2019	F - No patients seen	Neither
62	18/WA/0092	230113	Phase II multi-centre, double-blind, randomised trial of Ustekinumab in adolescents with new-onset type 1 diabetes	Yes	24/05/2019	1	80	81	04/10/2018	04/03/2019	21/09/2018	11/02/2019	05/03/2019	01/04/2019	D - Sponsor Delays	Sponsor
63	19/YH/0269	259860	The effects of seated exercise training on cardiorespiratory fitness in patients with diabetic foot ulcers: A Randomised Controlled Trial	No		52			11/09/2019	11/10/2019	09/09/2019	13/11/2019	02/12/2019	05/12/2019	D - Sponsor Delays	Sponsor
64	19/EM/0063	253607	A Double-Blind, Phase III, Randomised Study to Compare the Efficacy and Safety of Oral Azacitidine (CC-486) Versus Placebo in Subjects with Acute Myeloid Leukaemia or Myelodysplastic Syndromes as Maintenance after Allogeneic Haematopoietic Stem Cell Transplantation	No					06/02/2019	18/10/2019	14/05/2019				D - Sponsor Delays	Sponsor
65	18/EE/0197	246434	A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)	Yes	15/07/2019	18	56	74	20/11/2018	02/05/2019	10/08/2018	23/04/2019	20/05/2019	03/06/2019	F - No patients seen	Neither
66	16/NW/0621	206740	Phase 3, randomized, open-label, active-controlled study evaluating the efficacy and safety of oral vadadustat for the maintenance treatment of anemia in subjects with non-dialysis-dependent chronic kidney disease (NDD-CKD) (PRO2TECT-CONVERSION)	No		1			14/12/2018	01/04/2019	21/10/2016	20/03/2019	02/04/2019	11/06/2019	D - Sponsor Delays	Sponsor
67	19/EM/0027	256620	The efficacy of Transcutaneous Electrical Nerve Stimulation versus local anaesthetic cream in alleviating the pain of local anaesthetic injections in adults - A Randomised Controlled Trial	No		71			07/12/2018	15/04/2019	12/03/2019	25/06/2019	25/06/2019	25/06/2019	D - Sponsor Delays	Sponsor
68	18/SC/0243	240684	HPS-4/TIMI 65/ORION-4: A double-blind randomized placebo-controlled trial assessing the effects of inclisiran on clinical outcomes among people with atherosclerotic cardiovascular disease	Yes	27/08/2019	15	56	71	03/07/2018	17/06/2019	17/10/2018	25/06/2019	02/07/2019	22/08/2019	D - Sponsor Delays, F - No patients seen	Sponsor
69	19/WA/0028	233655	Brain TV (Tissue Velocimetry) for emergency assessment of acquired brain injury	Yes	01/08/2019	19	51	70	01/09/2018	23/05/2019	16/05/2019	06/06/2019	11/06/2019	11/06/2019	D - Sponsor Delays	Sponsor
70	18/WS/0060	241305	Persistence of inflammation and study of T2 pathways following inhibition of Interleukin-5 with Mepolizumab in severe eosinophilic asthma	Yes	03/06/2019	6	61	67	02/11/2018	28/03/2019	31/10/2018	25/03/2019	03/04/2019	30/04/2019		
71	18/YH/0322	226765	Single Use Negative pResure dressing for Reduction In Surgical site infection following Emergency laparotomy	Yes	18/07/2019	36	30	66	18/12/2018	13/05/2019	26/10/2018	13/05/2019	18/06/2019	11/07/2019		
72	18/ES/0119	245233	STopping Aminosaliclylate Therapy in Inactive Crohn?s Disease (STATIC) Study: A Randomized, Open-label, Non-inferiority Trial	No					07/11/2018	28/10/2019	09/11/2018					

Row No	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
73	18/LO/0543	242259	An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination, in patients with advanced solid/metastatic tumours.	Yes	17/07/2019	8	56	64	22/01/2019	14/05/2019	12/06/2018	17/05/2019	22/05/2019	03/06/2019		
74	19/EM/0101	260487	Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF): SCENIC Trial	Yes	13/08/2019	0	63	63	15/01/2019	11/06/2019	17/06/2019	06/06/2019	11/06/2019	03/07/2019		
75	19/LO/0343	255538	The PRECISE Protocol: Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization	No		36			13/08/2019	29/10/2019	12/08/2019	23/10/2019	04/12/2019	05/12/2019		
76	19/LO/1500	269558	Basic Evaluation Lead Post-Market Clinical Follow-up (BASIC) Study	No					12/09/2019	30/10/2019	29/10/2019	05/12/2019				
77	18/EM/0336	251477	A Phase 3 Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy	Yes	07/05/2019	4	57	61	31/05/2018	07/03/2019	19/12/2018	04/03/2019	11/03/2019	13/03/2019		
78	18/LO/1606	250789	A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera	No		16			28/11/2018	06/03/2019	05/10/2018	08/03/2019	22/03/2019	02/05/2019		
79	19/EM/0264	266058	In younger adults with unstable ankle fractures treated with close contact casting, is ankle function not worse than those treated with surgical intervention? The Fractured Ankle Management Evaluation (FAME) Trial.	No					31/10/2019	15/11/2019	03/09/2019					
80	19/SC/0418	261435	The effect of a multi-modal exercise intervention on patients with type 2 diabetes mellitus and impaired physical functioning: a randomised controlled trial.	No					16/09/2019	18/11/2019	24/09/2019					
81	18/SC/0427	220853	The efficacy and mechanism of surfactant therapy for critically ill infants with bronchiolitis: The Bronchiolitis Endotracheal Surfactant Study.	Yes	13/11/2019	27	16	43	10/07/2019	01/10/2019	15/10/2018	03/10/2019	28/10/2019	13/11/2019		
82	17/SC/0021	219693	The effects of combining electrical stimulation of the calf and thigh muscles in patients with osteoarthritis of the knee	Yes	14/06/2019	5	37	42	21/03/2018	03/05/2019	09/03/2017	02/05/2019	08/05/2019	14/05/2019		
83	19/WM/0178	262396	A multi-sited exploration of the ease of mainstreaming the Term Snuby?, mother-infant skin to skin undergarment, in all births up to the point of discharge from maternity services (<2 weeks).	Yes	09/12/2019	15	26	41	04/03/2019	29/10/2019	25/07/2019	29/10/2019	13/11/2019	13/11/2019		
84	19/EM/0267	262581	SPACE FOR COPD? delivered as a maintenance programme on Pulmonary Rehabilitation discharge: a randomised controlled trial evaluating the long-term effects on exercise tolerance and mental wellbeing	Yes	20/11/2019	0	41	41	11/11/2018	10/10/2019	10/10/2019	10/10/2019	10/10/2019	16/10/2019		
85	19/SC/0107	237804	A phase II trial assessing nivolumab in strong class II expressing microsatellite stable colorectal cancer	No		28			14/02/2018	17/10/2019	05/07/2019	01/11/2019	14/11/2019	25/11/2019		
86	18/EM/0310	239782	C-Stich2: Emergency Cervical Cerclage to Prevent Miscarriage and Preterm Birth: a Randomised Controlled Trial	No		36			10/12/2018	05/02/2019	16/11/2018	27/02/2019	13/03/2019	14/03/2019		
87	18/LO/1290	249002	A Randomized, Placebo-Controlled, Phase 2 Study of HB-101, a Bivalent Cytomegalovirus (CMV) Vaccine, in CMV-Seronegative Recipient (R-) Patients Awaiting Kidney Transplantation from Living CMV-Seropositive Donors (D+)	No					12/01/2018	25/11/2019	06/11/2018					

Row No	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
88	18/NW/0514	249725	SELECT - Semaglutide effects on cardiovascular outcomes in people with overweight or obesity	Yes	12/03/2019	16	20	36	13/06/2018	04/02/2019	03/01/2019	07/02/2019	20/02/2019	25/02/2019		
89	18/EM/0229	250101	A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PARALLEL-GROUP, ACTIVE-CONTROL STUDY OF THE EFFICACY AND SAFETY OF SPARSENTAN FOR THE TREATMENT OF IMMUNOGLOBULIN A NEPHROPATHY	Yes	01/03/2019	6	30	36	17/07/2018	24/01/2019	04/10/2018	12/11/2018	30/01/2019	06/02/2019		
90	19/LO/0128	234820	Multicentre prospective double-blind randomised controlled trial of the effect of intravenous iron supplementation, with or without exercise training, in iron-deficient but not anaemic patients with chronic kidney disease on exercise capacity, fatigue, skeletal muscle metabolism and physical function status.	Yes	14/08/2019	5	30	35	16/01/2019	10/07/2019	07/03/2019	07/03/2019	15/07/2019	06/08/2019		
91	19/EM/0258	266702	A randomised controlled trial of full milk feeds versus intravenous fluids with gradual feeding for preterm infants (30-33 weeks gestational age)	Yes	27/11/2019	27	7	34	10/09/2019	24/10/2019	13/09/2019	04/11/2019	20/11/2019	21/11/2019		
92	18/SS/0131	248427	A Randomised Controlled Trial to investigate the effectiveness of Thoracic Epidural and Paravertebral Blockade In reducing Chronic Post- Thoracotomy Pain: 2	Yes	11/02/2019	2	32	34	03/10/2018	08/01/2019	15/11/2018	04/01/2019	10/01/2019	22/01/2019		
93	19/LO/0855	260338	A Phase 2, randomized, non-comparative, open-label study of NKTR-214 in combination with nivolumab and of chemotherapy in cisplatin ineligible, locally advanced or metastatic urothelial cancer patients with low PD L1 expression	No		4			13/02/2019	20/09/2019	27/06/2019	11/09/2019	24/09/2019	21/10/2019		
94	17/LO/1875	219487	Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART): An international investigator-led phase III multi-arm multi-stage randomised controlled platform trial of adjuvant therapy in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse	No		28			05/04/2017	30/10/2019	08/01/2018	05/11/2019	27/11/2019	27/11/2019		
95	19/EE/0014	256539	A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE-CONTROLLED, MULTICENTER, 2-PART PHASE II STUDY ON REPLACEMENT OF STEROIDS BY IFX-1 IN ACTIVE GRANULOMATOSIS WITH POLYANGIITIS (GPA) AND MICROSCOPIC POLYANGIITIS (MPA)	No		26			01/06/2018	08/05/2019	02/05/2019	21/05/2019	03/06/2019	05/06/2019		
96	19/LO/0361	258316	Bioimpedence In Pregnancy and Labour: A fluid balance concept study (BIPAL study)	Yes	16/04/2019	19	8	27	07/01/2019	20/03/2019	20/03/2019	08/04/2019	08/04/2019	08/04/2019		
97	19/NW/0570	234906	A randomized, treatment open-label, dose-blinded parallel group, three arm, proof-of-concept clinical trial to investigate the efficacy and safety of LNP023 compared with rituximab in the treatment of subjects with idiopathic membranous nephropathy	No		0			22/03/2019	05/12/2019	28/10/2019	28/11/2019	05/12/2019			
98	17/NW/0637	229352	BiOmArkers in Urine, anTiHypeRtensive trEAtment and blood pressure Control in Hypertensive patients - OUTREACH Study	Yes	27/03/2019	20	6	26	22/12/2017	01/03/2019	20/12/2017	08/03/2019	21/03/2019	26/03/2019		
99	19/NW/0158	259931	SCIENCE Surgery or Cast for Injuries of the EpicoNdyle in Children?s Elbows:A multi-centre prospective randomised superiority trial of operative fixation versus non-operative treatment for medial epicondyle fractures of the humerus in children.	Yes	02/07/2019	20	5	25	13/03/2019	07/06/2019	25/03/2019	11/06/2019	27/06/2019	01/07/2019		
100	18/WA/0199	108978	A randomised, placebo controlled trial of azithromycin for the prevention of chronic lung disease of prematurity in preterm infants	Yes	09/10/2019	21	2	23	19/06/2018	16/09/2019	29/06/2018	17/09/2019	07/10/2019	08/10/2019		
101	18/LO/2113	240789	Outcomes in children referred for chronic cough and clinical markers for presence of bronchiectasis	Yes	01/02/2019	0	18	18	21/09/2018	14/01/2019	09/01/2019	14/01/2019	14/01/2019	14/01/2019		

Row No	REC No	IRAS No	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
102	18/NE/0052	234786	A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients with C3 Glomerulopathy	No					25/07/2019	17/12/2019	24/04/2018					
103	18/YH/0396	250694	The Cognition and Flow Study: The Effects of Brain Training on Brain Blood Flow	Yes	22/01/2019	5	8	13	14/08/2018	09/01/2019	08/01/2019	10/01/2019	14/01/2019	14/01/2019		
104	19/SS/0067	260562	The British Society of Endovascular Therapy Conformable Endovascular Aneurysm Repair Registry	No					11/09/2019	23/12/2019	30/05/2019					